文献速递瓣膜外科

连续500例快速部署外科主动脉瓣手术的中期结局

Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures†.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该研究基于前瞻性单中心数据库,纳入2010年5月至2017年7月连续500例接受Edwards INTUITY快速部署主动脉瓣的严重主动脉瓣狭窄患者,平均年龄73.5岁(SD 7.9),女性占45.6%,中位随访12个月,累计818患者年。结果显示30天死亡率0.8%(4/500),1、3、5年总生存率分别为94%、89%、81%,瓣膜血流动力学和耐久性良好,但新起搏器植入率为8.6%,作者认为植入需专门培训且起搏器植入率仍值得关注。

要点

  • 30天死亡率为0.8%(4/500),1、3、5年总生存率分别为94%、89%、81%。
  • 出院及1、3、5年平均跨瓣压差分别为13(SD 5)、11(SD 4)、12(SD 5)、11(SD 3)mmHg。
  • 新起搏器植入率为8.6%,作者认为该比率仍值得关注。

核心结论

  • 该快速部署主动脉瓣在血流动力学性能、耐久性和安全性方面显示出优异结果。
  • 植入需要专门培训,起搏器植入率仍值得关注。
  • 该新型瓣膜便于微创入路,并可能在复杂联合手术中获益。

研究设计与样本

  • 单中心前瞻性持续数据库研究,纳入连续500例严重主动脉瓣狭窄并接受快速部署主动脉瓣的患者,女性占45.6%,平均年龄73.5岁(SD 7.9),手术时间为2010年5月至2017年7月。
  • 中位随访时间为12个月,累计随访818患者年。
  • 评估术前特征、手术参数、生存率、瓣膜相关不良事件和瓣膜血流动力学。

主要发现

  • 30天死亡率为0.8%(4/500),1年、3年、5年总生存率分别为94%、89%、81%。
  • 236例(47%)选择微创手术入路,其中122例(24%)经右前胸廓切开。
  • 孤立主动脉瓣置换的全胸骨切开组阻断时间和体外循环时间分别为53(SD 17)分钟和89(SD 29)分钟,微创手术入路组分别为75(SD 23)分钟和110(SD 31)分钟(P < 0.001)。
  • 出院时及术后1、3、5年平均跨瓣压差分别为13(SD 5)、11(SD 4)、12(SD 5)、11(SD 3)mmHg。
  • 新起搏器植入率为8.6%;6年后注册1例(0.2%)结构性退化;因非结构性功能障碍或心内膜炎行瓣膜取出9例(1.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprosthesis. METHODS: Five hundred consecutive patients, of whom 45.6% were female with a mean age of 73.5 [standard deviation (SD) 7.9 years], with severe aortic stenosis who received a rapid deployment aortic valve between May 2010 and July 2017 were included in a prospective and ongoing database. The median follow-up time was 12 months, and the total accumulated follow-up time was 818 patient years. Preoperative characteristics, operative parameters, survival, valve-related adverse events and valve haemodynamics were assessed. RESULTS: Thirty-day mortality was 0.8% (4/500), and overall survival at 1, 3 and 5 years was 94%, 89% and 81%, respectively. A minimally invasive surgical approach was chosen in 236 patients (47%), of which 122 (24%) were operated on through an anterior right thoracotomy. Cross-clamp and cardiopulmonary bypass times for isolated aortic valve replacement were 53 (SD 17) and 89 (SD 29) min for full sternotomy as well as 75 (SD 23) and 110 (SD 31) min for minimally invasive surgery approaches (P < 0.001). Mean gradients at discharge, 1, 3 and 5 years were 13 (SD 5), 11 (SD 4), 12 (SD 5) and 11 (SD 3) mmHg, respectively. New pacemaker implantation was necessary in 8.6% of patients. A single case (0.2%) of structural degeneration was registered after 6 years. Valve explantation for non-structural dysfunction or endocarditis occurred in 9 patients (1.8%). CONCLUSIONS: This rapid deployment aortic valve has shown excellent results concerning haemodynamic performance, durability and safety. Implantation requires specific training, and the rate of pacemaker implantation remains a matter of concern. This novel valve also facilitates minimally invasive approaches and may be beneficial in complex combined procedures.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Andreas M, Coti I, Rosenhek R, et al. Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures†. Eur J Cardiothorac Surg. 2019. PMID: 30137264. doi:10.1093/ejcts/ezy273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。